The GlcNAc-mimicking peptide failed to bind to the amelogenin trityrosyl motif peptide when the tyrosyl residues were substituted with phenylalanine or when the third proline was replaced with threonine, as in some cases of human X-linked amelogenesis imperfecta. This study documents that molecular mimicry may play a role in stability and organization of amelogenin during amelogenesis.
Dental enamel is derived through the biomineralization of an extracellular organic matrix secreted by the ameloblast cells of the inner enamel epithelium. Although ameloblasts synthesize several other proteins, including cytokeratin 14 prior to synthesis of amelogenins (1), the amelogenins constitute some 90% of the secretory stage enamel matrix proteins (2) (3) (4) . Previously, we have hypothesized that amelogenins may bind to sugar residues of enamel matrix glycoproteins facilitating the biomineralization process (5) . The hypothesis was supported by identification of a stoichiometric interaction specifically between amelogenins and the GlcNAc residues of glycoconjugates (5) . Further, we have identified the glycobinding locus of the amelogenin structure in a highly conserved motif (-PYPSYGY-) located at the carboxyl-terminal of the tyrosine-rich amelogenin polypeptide (TRAP). 1 Remarkably, this trityrosyl motif has a striking structural similarity to the GlcNAc-binding domain of several GlcNAc-specific lectins (5-7).
Recent observations have indicated that the GlcNAc-binding motif of several lectins such as wheat germ agglutinin (WGA) and lectins from Datura stramonium, Lycopersicon esculentum, Solanum tuberosum, and Wisteria floribunda also recognize and bind to a specific peptide sequence that mimics GlcNAc found in cytokeratins (8) . The present study is based on the hypothesis that comparable interactions between the amelogenins and GlcNAc-mimicking peptides (GMp) may occur during amelogenesis with implications for the understanding of the control of normal enamel development and of the molecular lesions that underlie enamel pathologies such as the condition of amelogenesis imperfecta.
In this investigation, we demonstrate that a conserved GMp motif of cytokeratins specifically binds to the amelogenin trityrosyl motif peptide (ATMP). Further, we have directly tested the likely biological relevance of GMp-amelogenin interactions showing that loss of function mutations of the ATMP sequence correlates with loss of interaction with GMp, specifically that the substitution of a proline residue of ATMP (with threonine) as recently observed in a case of human X-linked amelogenesis imperfecta (AI) (9) strongly abrogates the GMp-amelogenin interaction.
EXPERIMENTAL PROCEDURES
Amelogenin Proteins--The following amelogenin polypeptides (Fig. 1) were used: (i) rM179 (20.16 kDa), a recombinant mouse amelogenin, which is identical to the native murine amelogenin, M180 (except for the lack of the amino-terminal methionine residue (10) and a phosphorylated serine at position 16) (11, 12) ; (ii) rM166 (18.6 kDa), as rM179 but lacking the 13 C-terminal amino acid residues (13); (iii) TRAP (5.20 kDa), a synthetic murine tyrosine-rich amelogenin polypeptide representing the N-terminal 45 amino acid residues of the M180 amelogenin; (iv) LRAP (6.82 kDa), synthetic leucine-rich amelogenin polypeptide, identical to the full-length (M180) amelogenin at its two termini but lacking the center portion of the protein (14) ; (v) amelogenin C-terminal peptide (ACP); (vi) P173 (25 kDa) and P148 (20 kDa) (porcine amelogenins were extracted and purified following the protocol of Fincham et al. (15) as described previously (5)); and (vii) ATMP, PYPSYGYEPMGGW and two altered ATMP peptides in one of which 1 The abbreviations used are: TRAP, tyrosine-rich amelogenin polypeptide; LRAP, leucine-rich amelogenin polypeptide; WGA, wheat germ agglutinin; GMp, GlcNAc mimicking peptide; ATMP, amelogenin trityrosyl motif peptide; T-ATMP, ATMP where proline is replaced by threonine; F-ATMP, ATMP where tyrosine is substituted by phenylalanine; ACP, amelogenin carboxyl-terminal peptide; HA, hemagglutination; HAI, hemagglutination inhibition; HSA, human serum albumin; HPLC, high performance liquid chromatography; TBS, Tris-buffered saline; AI, amelogenesis imperfecta; GM-peptide, GlcNAc-mimicking peptide; CK-14, cytokeratin-14; PVDF, polyvinylidene difluoride; BSA, bovine serum albumin. the third proline is substituted with threonine (T-ATMP) (PYPSYG-YETMGGW), and in another, all three tyrosine residues are replaced by phenylalanine (F-ATMP) (PFPSFGFEPMGGW) as described earlier (5) (see Fig. 1 ).
A typical reverse phase HPLC profile of rM179 and electrophoretic homogeneity of rM179, rM166, and the synthetic peptides TRAP and LRAP used in this investigation were shown and described earlier (5) . The purified preparations (rM166) were devoid of or had negligible contamination with vector proteins.
Decapeptides Mimicking GlcNAc-Synthetic GlcNAc-mimicking peptide (GM-peptide) with the cytokeratin amino acid sequence SFGSGF-GGGY (GMp1) and its variants (GMp2 to -8) with single amino acid substitutions (Table I) were used in this investigation. These peptides are known to bind to anti-GlcNAc monoclonal antibody and also to GlcNAc-specific lectins such as WGA, U. europaeus 11 (UEA-II), and that of D. stramonium and S. tuberosum, expressing functional similarity to the carbohydrate (8) . The atomic mass units of these synthetic GM-peptides range from 935 to 888 (Table I) . In order to identify the amino acid residues of the peptide sequence critical for binding to the tyrosyl motif of amelogenins, the pentamers (first and second half) of the GMp1 (SFGSGFGGGY), "SFGSG" and "FGGGY," were synthesized and used to inhibit the amelogenin or TRAP-mediated hemagglutination.
Synthesis and Purification of Polypeptides-All of the polypeptides, (GMp variants, the two pentamers, TRAP, and LRAP) used in this investigation were synthesized by the USC microchemical Core Laboratory using an Applied Biosystems model 430A one-column peptide synthesizer with the modified Merrifield procedure (16). Peptides were purified by reversed-phase HPLC (C4 -214TP54 column or C18 -291HS54 column; Vydac/The Separations Group, Hesperia, CA) with a gradient of 35-50% B in 60 min (buffer B contained 60% (v/v) aqueous acetonitrile in 0.1% (v/v) trifluoroacetic acid, and buffer A contained 0.1% trifluoroacetic acid) at a flow rate of 1.0 or 0.5 ml/min for small peptides depending on their size (5) .
Radiolabeling GMp1-The decapeptide SFGSGFGGGY (GMp1) was also labeled with 3 H (Amersham Pharmacia Biotech) to identify the specific binding to amelogenins. SFGSGFGGG [ 3 H]Y was prepared from tritium gas by Amersham Pharmacia Biotech. The product was purified by high performance liquid chromatography on a Vydac C18 300-Å (protein and peptide) (250 ϫ 4.6 mm) column with a gradient of buffer A (0.01 M trifluoroacetic acid, aqueous) and buffer B (0.01 M trifluoroacetic acid in acetonitrile), 0 -100% B over 30 min, at a flow rate of 1.0 ml/min. The peptide was supplied in an aqueous solution in a silanized borosilicate multidose vial with additional screw-cap under argon. The peptide was stored in the absence of light and air at 4°C.
Positive and Negative Controls-GlcNAc, chitobiose, chitotetraose, and WGA (Sigma) were used as positive controls and D-(ϩ)-glucosamine, LRAP, and BSA (Sigma) as negative controls.
Hemagglutination Inhibition (HAI) Assay-The HAI assays were performed in 8 ϫ 12-microtiter plates, with U-bottomed wells, after assessing the HA activity of the recombinant amelogenin/TRAP molecules as described earlier (5) . Previously, we have screened a variety of mammalian erythrocytes and selected mouse erythrocytes for effective HA by amelogenins including both rM179 and TRAP. We have selected the concentration of rM179/TRAP that gives two-well agglutination. All GMps were diluted (1:10 in Tris-buffered saline (TBS), pH 6.3) in Eppendorf tubes and were warmed to 30°C. To each well, 12.5 l of peptide solutions were added. The final concentration of peptides/well was adjusted to and ranged from 1 pM to 1 mM at 10-fold dilution. 6 g/12.5 l of amelogenin or 3 g/12.5 l of TRAP (diluted in trifluoroacetic acid (0.04%) ϩ TBS, pH 6.3), or TBS (pH 6.3) capable of two-well agglutination was added to each well and incubated for 1 h at 25°C. After incubation, 25 l of a 1.5% suspension of mouse erythrocytes (purchased from Crane Laboratories, Inc., Syracuse, NY) in TBS, pH 7.2, was added to all the wells. The plates were covered with parafilm, subjected to gentle low speed vortex for 10 s, and incubated at 25°C, and scoring was done after 2 h. The HAI titers were reported as the reciprocal of the lowest concentration of the inhibitors giving complete HAI (button formation) after 2 h.
Dose-dependent Binding of 14 C-GlcNAc to TRAP Molecules-A known amount of [ 14 C]GlcNAc (2 ϫ 10 4 cpm) in 100 l of TBS (pH 7.2) was added to polypropylene microcentrifuge tubes containing 100 l of increasing amounts of TRAP molecules in 0.04% trifluoroacetic acid. The mixture was incubated under constant agitation for 90 min at 25°C and precipitated with 1 ml of cold ethanol (200 proof; Gold Shield Chemical Co., Hayward, CA) at 4°C for 20 min. The tubes were then centrifuged for 15 min at 12,000 ϫ g in a Beckman Microfuge 12, and the supernatant was removed. The unbound 14 C-labeled GlcNAc was removed completely by repeated vortex mixing and washing three times with cold ethanol. Washing three times with ethanol did not affect the bound peptides. The final pellets were dissolved in 1 N NaOH, and the radioactivity was measured 15 min after adding 4 ml of scintillation 2) was added and mixed. 100 l of rM179 (7.5 nmol) or TRAP (20 nmol) in 0.04% trifluoroacetic acid were added to the mixture and incubated for 90 min at 25°C on a rotator. After incubation, the proteins were precipitated with 1 ml of cold ethanol at 4°C for 20 min and centrifuged for 15 min at 12,000 ϫ g. The unbound radioactive GlcNAc was removed completely by repeated vortex mixing and washing, three times with ethanol. The final pellets were dissolved in 50 l of 1 N NaOH, and the bound radioactivity was measured with 4 ml of scintillation fluid (Bio-safe 11) in a ␤-counter as mentioned earlier (5) 2) was added to polypropylene microcentrifuge tubes containing increasing amounts of rM179 or TRAP molecules in 0.04% trifluoroacetic acid, and the mixture was gently shaken every 20 min for 2 h at 37°C. After incubation, the samples were pelleted with 1 ml of cold ethanol at 4°C for 20 min and centrifuged for 15 min at 12,000 ϫ g, and the supernatant was removed. The unbound radioactive peptides were removed completely by repeated vortex mixing and washing four times with ethanol, which did not affect the bound peptides. The final pellets were dissolved in 1 N NaOH, and the bound radioactivity was measured 15 min after adding 4 ml of scintillation fluid (Amersham Pharmacia Biotech) in a ␤-counter. BSA and WGA were used as negative and positive controls, respectively.
Binding of 3 H-Labeled GMp1 to Amelogenins by Western Blot
Analysis and Autoradiography-Purified recombinant murine amelogenins (rM179 and rM166) were resolved via SDS-polyacrylamide gel electrophoresis using 15% resolving and 3.5% stacking gels (17) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp.; Immobilon-P Transfer Membrane) at 100 mA for 1 h using a semidry transblot apparatus (Hoefer Scientific Instruments, San Francisco) (18) . Protein transfer was assessed by staining the PVDF strips with 0.1% Fast Green (Sigma) in 40% acetic acid and 10% methanol, and the strips were compared with Coomassie Blue-stained protein bands (19) . Replicas were treated with [ 3 H]GMp1 (7 ϫ 10 7 dpm/ml) resuspended in phosphate-buffered saline (pH 6.0) for 18 h at 25°C, after blocking the membrane with phosphate-buffered saline, 1% HSA for 1 h at 37°C. The membranes were washed five times with phosphate-buffered saline, 0.1% HSA (20) . After washing and drying, the membranes were exposed to hyperfilm-3 H (Amersham Pharmacia Biotech) for 8 days at 25°C, and the films were developed manually.
Specific Binding of [ 3 H]GMp1 to TRAP as a Function of Increasing Concentration of GMp1 and Scatchard Plot Analysis-The total binding of [
3 H]GMp1 to TRAP was determined in duplicates using increasing concentrations of [ 3 H] GMp1 (40 -700 pmol) to 20 nmol of TRAP molecules. The nonspecific binding of [ 3 H]GMp1 was determined in duplicate in the presence of 40 nmol of unlabeled GMp1, and it was subtracted from the total binding to obtain the specific binding. A Scatchard plot analysis of this specific binding was carried out.
Inhibition of [ 3 H]GMp1
Binding to TRAP in the Presence of Unlabeled GMp1 or GlcNAc-100 l of unlabeled GMp1 or GlcNAc in TBS (pH 7.2) with increasing concentrations were prepared in duplicates in microcentrifuge tubes. To each concentration of unlabeled peptide or GlcNAc, 100 l of [ 3 H]GMp1 (30 ϫ 10 4 dpm in TBS, pH 7.2) was added and mixed. TRAP (25 nmol/100 l in 0.04% trifluoroacetic acid) was added to the mixture and gently shaken every 20 min for 2 h at 37°C. After incubation, the samples were precipitated with 1 ml of cold ethanol and centrifuged for 15 min at 12,000 ϫ g. The unbound [ 3 H]GMp1 was removed completely by repeated vortex mixing and washing four times with ethanol, and the bound radioactivity was measured with 4 ml of scintillation fluid (Amersham Pharmacia Biotech) in a ␤-counter as mentioned earlier (5 ]GlcNAc) to different amelogenins was measured by solid matrix assay, using 96-Remova-well strips in a microtiter plate (Costar Brand, VWR Scientific Products). Antigen coating was done by adding a solution of 100 l (5 nmol/well) of polypeptides (rM179, rM166, TRAP, LRAP, ACP, ATMP, T-ATMP, F-ATMP, porcine amelogenins, 20 and 25 kDa) in carbonatebicarbonate buffer (pH 9.6) to microtiter wells in triplicate and kept at 25°C overnight. Most amelogenin-derived polypeptides are soluble in the physiological range of pH (21) . WGA and BSA were used as positive and negative controls, respectively. Wells were blocked with 0.1% HSA in TBS, pH 7.2 for 2 h at 37°C. 100 l of [ 3 H]GMp1 (30 ϫ 10 4 dpm) in TBS (pH 7.2) were added to wells and incubated for 2 h at 37°C with gentle shaking once every 20 min. After incubation, the unbound peptide was removed and washed three times with TBS (pH 7.2). The wells were transferred to scintillation vials. The bound radioactive peptide was released into the 4 ml of scintillation fluid (Safety-Solve, Research Products International Corp.) by continuous shaking and vortexing for 15 min and counted for bound radioactivity in a ␤-counter. The above assay was also used to test inhibition of [ Statistical Analysis-Descriptive statistics were calculated throughout. In addition, Mann-Whitney sample test and regression analyses (linear and polynomial curve fit, r 2 , and test of significance of slope) were carried out using Origins software (Microcal Software Inc.). Twotailed p values were obtained to assess the level of significance.
RESULTS
Purification of Synthetic GMps-GMp with the amino acid sequence SFGSGFGGGY (GMp1) and its variants (GMp-2 to -8) with single amino acid substitution (marked in boldface type in Table I ) were purified by reverse phase HPLC, and a typical profile of GMp1 is illustrated in Fig. 2 .
HAI of rM179 and TRAP by GMps-The peptide binding specificity of purified rM179/TRAP molecules was probed by peptide inhibition of HA. GlcNAc-mediated HAI was used as a positive control. Table I shows the nature of GMps that inhibited HA of amelogenin and of TRAP. Of the peptides tested, only GMp1 and GMp4 inhibited the HA of rM179. None of the other GMps inhibited the HA of amelogenins even at 1000-fold higher concentrations. The substitution of the serine or phenylalanine residues of GMp1 significantly affected the binding. Both GMp1 and GMp4 inhibited the HA at 150 nM concentration, which is the same as with the dimer and tetramer of GlcNAc. The binding of GlcNAc to rM179 is 10-fold less than that of GMp1, suggesting that GlcNAc is the preferred ligand of rM179 than GMp1.
In contrast, GMp1 is the most potent inhibitory peptide of TRAP-HA. The binding of GMp1 to the TRAP molecule is 20-fold stronger than that of GlcNAc, suggesting that GMp1 is the preferred ligand of TRAP. TRAP-HAI of GMp1 occurred at a concentration as low as 500 pM, whereas 500 nM of GMp4 is required to cause such inhibition. The inhibitory potency of GMp1 is 1000-fold greater than that of GMp4 or GMp2. The substitution of serine (as in GMp5 and GMp7) or phenylalanine residues (as in GMp3, GMp6, or GMp8) or changing the terminal tyrosine (as in GMp2 and GMp4) least affected HAI. The binding affinity for GlcNAc versus GMp1 appears to change with processing of the larger amelogenins (rM179) to TRAP.
Inhibition of rM179/TRAP-mediated HA by SFGSG and FGGGY of GMp1-To identify and minimize the amino acid sequence responsible for binding to the tyrosyl TRAP motif of amelogenins, the pentamers were used to inhibit the amelogenin-or TRAP-mediated HA. The pentamer, FGGGY, did not affect amelogenin-or TRAP-mediated HA, whereas SFGSG, representing the amino-terminal half of the GMp1 inhibited the TRAP-mediated HA partially compared with the full-length GMp1 (see Table I 14 C]GlcNAc. 50% inhibition of GMp1 and GMp4 occurred at 150 M and 130 M, whereas inhibition by cold GlcNAc required a higher concentration (250 M) (Fig. 4A) . The relative inhibitory potencies of GMp1 and GMp4 are about 2-fold more efficient than cold GlcNAc, a finding different from that for HAI in which GlcNAc showed a 10-fold increase in inhibitory potency. However, both GMp1 and GMp4 were preferred ligands of rM179 in both assays. Furthermore, GMp1 strongly and dosimetrically inhibited the binding of [
14 C]GlcNAc to TRAP. The relative inhibitory potency of GMp1 is 2.5-fold more efficient than cold GlcNAc (Fig. 4B) , a finding in conformity with HAI observations in which GMp1 is more potent than GlcNAc in inhibiting TRAPmediated HA. None of the other peptides inhibited the interaction of TRAP with [
14 C]GlcNAc in the solid matrix assay. Therefore, GMp1 is the more preferred peptide ligand inhibiting the lectin-like activity of rM179 and the TRAP molecule.
Direct Binding of [ 3 H]GMp1 to rM179 and TRAP-The binding of [
3 H]GMp1 increased as the concentration of rM179/ TRAP increased in a dose-dependent manner (Fig. 5, A and B) as evidenced by a consistent polynomial fit with significant slope (p Ͻ 0.001) and r 2 (0.97 for rM179 and 0.93 for TRAP). WGA used as the positive control also showed a similar slope (Fig. 5A, table inset) . LRAP, a negative control, showed minimal and no dose-dependent binding to [ 14 C] GlcNAc binding of TRAP, we selected TRAP to further investigate the specific binding of GMp1 (Fig. 5B) .
TABLE I Inhibition of hemagglutination of rM179 or TRAP by GlcNAc, its oligomers, GMps, and their fragments
Purified peptides (12.5 l), serially diluted in TBS, pH 6.3, were added to microtiter wells and mixed with rM179 (6 g/12.5 l) or TRAP (3 g/12.5 l) previously adjusted to give two-well agglutination. After 60 min of incubation of 25°C, 25 l of 1.5% suspension of fresh mouse erythrocytes (TBS, pH 7.2) were added to each microtiter well and mixed. The hemagglutination titer was determined after 2-h incubation at 25°C. The relative inhibitory potency of each peptide is indicated. ND, not tested. 
Competitive Binding of [ 3 H]GMp1 and Unlabeled GMp1 to TRAP-Unlabeled GMp1 inhibited the binding of [
3 H]GMp1 to TRAP stoichiometrically. The inhibition slope for GMp1 (p Ͻ 0.001) and GlcNAc (p Ͻ 0.0001) and r 2 for GMp1 (Ϫ0.98) and GlcNAc (Ϫ0.99) establish significant stoichiometry (Fig. 7) . Comparison of the slope or the 50% inhibition showed that GMp1 is 4-fold more potent than cold GlcNAc in binding to TRAP, a finding in conformity with GMp1 inhibition of HA (Table I ) and binding of [ 14 C]GlcNAc to TRAP (Fig. 4B) .
Binding of GMp1 to the GlcNAc-binding Trityrosyl Motif of Amelogenin Is Affected by Substitution of Tyrosyl Residues or
Third Proline-The specific binding of GMp1 to TRAP is further confirmed in a solid matrix assay in which [ 3 H]GMp1 bound to rM179 and rM166 (lacking the 13-residue ACP) but failed to bind to ACP per se, suggesting that the ACP is not required for binding. 33 amino acids of the 45 amino acid residues of the N-terminal TRAP region are also shared by LRAP (see Fig. 1 ). In addition, LRAP possesses 26 amino acid residues of the C terminus of the larger (rM179) amelogenins. Failure of [ 3 H]GMp1 to bind to LRAP indicates that the Nterminal 33 amino acid residues of TRAP are not recognized by the GMp1 as was previously reported for GlcNAc (5) . Therefore, the specific binding motif of GMp1 lies in the 13 amino acids of the C-terminal residues of TRAP, namely PYPSYGYEPMGGW (the trityrosyl motif or ATMP). Indeed, [ 3 H]GMp1 bound avidly to the trityrosyl motif or ATMP (Fig. 8) . Fig. 8 shows that the binding of [ 3 H]GMp1 to both TRAP and ATMP is almost identical to [ 14 C]GlcNAc (5) and is significantly greater than that to LRAP or ACP. However, substitution of the third proline in ATMP by threonine (T-ATMP) and substitution of all three tyrosine residues by phenylalanine (F-ATMP) resulted in complete loss of binding of the peptide to GMp1, identical with the observations previously made with GlcNAc (5). (11, 12) . They consist of a single polypeptide chain of some 180 amino acids and are highly conserved across species. Further, there is some variation in amelogenin protein size between species and also as a result of alternative splicing of the primary RNA (15, (23) (24) (25) (26) . Concomitant with enamel biomineralization, the primary amelogenin is proteolytically processed from the C-terminal end to smaller fragments, among which TRAP, consisting of the 45 N-terminal residues, is prominent (27-29) .
The recombinant amelogenin (rM179), which corresponds to the newly secreted murine amelogenin (M180), has the capability of preferentially agglutinating mice erythrocytes (5). Agglutination of erythrocytes or HA requires multiple (polyvalent) binding sites of a protein to interact with several erythrocytes. Our previous observations confirmed that the ATMP, a highly conserved 13-amino acid motif of the TRAP region, is the only and the specific site of GlcNAc binding. Assuming that it is this site that is solely responsible for binding to GlcNAc residues on erythrocyte surfaces to bring about HA, then HA would not be achieved by a single amelogenin polypeptide but by an aggregate of amelogenins that creates multivalent binding sites (5) . It has been well documented that both native and recombinant amelogenins possess selfassembly properties both in vivo and in vitro, forming supramo- Removawell plates were coated in triplicate with 100 l of 5 nmol of protein/ peptide in carbonate buffer (pH 9.6) overnight at 25°C. Unbound proteins/peptides were removed and blocked with 0.1% HSA in TBS (pH 7.2). Radiolabeled GM-peptide (100 l, 30 ϫ 10 4 dpm) in TBS (pH 7.2) was added and incubated for 2 h at 37°C. The unbound GMp1 was removed by washing the plates three times, with TBS, and the radioactivity was measured. WGA and BSA were used as positive and negative controls, respectively. The background values (uncoated wells) are also presented in the figure. S.D. of triplicate analyses for each test material and two-tailed p values after nonparametric analyses are indicated. lecular quasi-spherical "nanosphere" structures (30, 31) . If amelogenin assemblies can also facilitate binding to GlcNAc residues on erythrocytes, as evidenced by inhibition of amelogenin-mediated HA by GlcNAc, this suggests that the ATMP motif may not be involved in the self-assembly process, in contrast to the earlier suggestion (32) .
The ability of the TRAP molecule to also promote HA suggests that TRAP per se may be capable of self-assembly to a polyfunctional structure. Indeed, our recent studies employing AFM imaging confirm that TRAP as well as LRAP, which contains the remaining N-terminal sequence of TRAP, are capable of self-assembly. 2 Such an assembly may not involve the ATMP locus, since both GlcNAc and GMp1 specifically bound to ATMP (Fig. 5 in Ref. 5; Fig. 8) . Thus, the two domains of TRAP, the 33-residue N-terminal sequence preceding ATMP involved in self-assembly and the ATMP per se that bind to erythrocytes, bring about HA. It is suggested that in vivo GlcNAc binding may protect ATMP from proteolysis, and, hence, the lectin-like functional role of amelogenins may preserve TRAP during enamel biomineralization.
A Decamer Peptide (GMp1) of Cytokeratin 14 Also Inhibits HA of rM179 and TRAP-In a similar manner to GlcNAc, a decamer (SFGSGFGGGY; GMp1) was found to inhibit rM179-or TRAP-mediated HA. This amino acid sequence is found in cytokeratin-14 (CK-14) (8), a cytosolic component of ameloblasts (1), and of the epithelial cell lineage that secretes amelogenin. We have modified synthetic GMp1 by substituting different serine residues with alanine or altering the terminal tyrosine residue. All of the modified GMps, except one, failed to inhibit rM179 or TRAP-mediated HA (Table I) (Fig. 7 ) further reinforce the view that both GMp1 and GlcNAc are competing for one and the same binding site. These observations provide the first evidence for specific amelogenin-peptide interactions.
These findings also suggest that although amelogenins may function as lectins they are also capable of binding specifically to peptides. Some recent reports provide evidence that lectins are not solely specific for sugar residues but are also capable of binding specifically to peptides, leading to a category of peptides known as "sugar-mimicking peptides" (33) (34) (35) (36) . The list of such sugar-mimicking peptides is restricted to a few sugars such as GlcNAc (8) but may expand with the possibility of sugar-mimicking peptides simulating glycosidic linkages of dimer or of polymeric sugars (37) . The FabЈ portion of antiidiotype of sugar-specific monoclonal antibodies (8, 19, 38, 39) represents sugar-mimicking peptides. Several GlcNAc binding lectins such as D. stramonium, L. esculentum, S. tuberosum, and W. floribunda are capable of binding to GMp1 and other GMps (8) , although the potency of the binding may vary with the lectin. In the present study, we show that amelogenins preferentially bind GMp1. Although GMp1 is also known to inhibit GlcNAc interaction with WGA (present study and Ref. (40 -42) have shown that hypoplastic and hypocalcified AI teeth contained increased protein content (2%) compared with normal primary enamel (0.3%) and attributed the protein retention in enamel to defective mineralization. They have linked the defects in enamel formation to a variety of mutations of the X-chromosome amelogenin gene. In genetic studies on two unrelated human pedigrees for AI, separate, single amino acid changes were shown to occur within the highly conserved TRAP region. We have replaced the third proline of the synthetic ATMP polypeptide with threonine (T-ATMP), as has been found in some cases of human X-linked AI (9) and also substituted with phenylalanine (F-ATMP) all three tyrosine residues. Not only did GlcNAc fail to bind to T-ATMP and F-ATMP (5), but so did GMp1 (Fig. 8) , confirming that mutations of ATMP that cause enamel defects also result in loss of binding to GMp1. The failure of GMp1 to bind to phenylalanine substituted ATMP suggests the hydrophilic nature of GMp1-ATMP interaction.
The Table II shows that GMp1 is a better ligand than GlcNAc. The difference in the ligands can be attributed to the molecular size difference between GlcNAc and GMp1, which must be confirmed after comparing the binding affinity of GMp1 with GlcNAc-oligosaccharides. In the HAI assay, GlcNAc was the preferred ligand for rM179, whereas the preference changed from GlcNAc to GMp1 after proteolytic conversion to TRAP indicating a modulation of the receptor affinity of amelogenin during proteolytic processing. Purification of TRAP from enamel generally results in the isolation of two forms of the molecule, one with 45 amino acids and another with 43 amino acids lacking the C-terminal glycine 44 and tryptophan 45 (43) (44) (45) . We have suggested earlier that the formation of the 45-and 43-mer TRAPs may possibly depend on whether the amelogenin is bound to GlcNAc or not, since the COOH-terminal MGGW sequence may constitute the binding pocket of GlcNAc (5). The 10-fold higher HAI potency of GlcNAc to arrest 2 A. G. Fincham, unpublished observations. rM179-mediated HA and the shift in HAI potency (GMp1 inhibitory potency being 20-fold greater than GlcNAc) after proteolytic conversion of amelogenin into TRAP suggest that consequent upon conversion, TRAP may shift its binding affinity from GlcNAc to GMP1, the carrier of which remains to be identified. Does GMp1 Carrier Protein Exist within the Enamel Matrix?-Several investigators have identified GMp1 as a conserved motif of cytokeratins (8, 46, 47) . CK-14 has been identified immunochemically in secretory stage ameloblasts (1, 48, 49) and is considered as a marker for ameloblasts in a developing tooth with expression preceding synthesis of amelogenins. While one can envisage interaction of intracellular amelogenins with the GMp1 motif of ameloblast cytoplasmic CK-14, the interaction of amelogenins with a GMp1 structure within the extracellular matrix remains to be documented. Rugg et al. (50) have reported the presence of discolored and notched front teeth in a child with a functional "knockout" of CK-14, displaying clinical symptoms of epidermolysis bullosa. Some earlier immunohistological observations of Robinson et al. (51) have suggested the presence of "keratins" within the protein matrix of enamel, but the presence of a GMp1 polypeptide or of proteolytic fragments of CK-14 in the organic matrix of enamel remains to be demonstrated.
In conclusion, this investigation, an extension of our earlier discovery of a novel lectin-like function for the amelogenins, provides evidence for specific amelogenin-peptide interactions by sugar-mimicking polypeptide motifs. Both GMp1 and GlcNAc are shown to compete for the same binding site on amelogenins. This binding site was identified to be the trityrosyl motif of the amelogenin TRAP sequence. Modifications of this polypeptide motif, including the substitution of proline 3 by threonine as observed in a case of human X-linked AI, resulted in a loss of binding to both GlcNAc and GMp1. While GlcNAc appears to be the preferred ligand of the full-length amelogenin, the ligand affinity shifts to GMp1 after proteolytic conversion of amelogenin into TRAP. Such molecular tailoring leading to a change in ligand affinity may be an event associated with enamel maturation. While cytokeratin 14 carries the GMp1 motif, it has not been identified within the extracellular matrix, and the significance of the specific interactions described in this study require further clarification. The binding affinity of amelogenins for a cytokeratin motif suggests that amelogenins are "cytokeratin (intermediate filament)-binding proteins," similar to plectin, nestin, and desmocalmin (22) . Phosphorylation of intermediate filament-binding proteins results in their dissociation from intermediate filament (22) . In this context, phosphorylation of serine 16 of amelogenins is of interest. We may postulate that (i) intracellular cytokeratinamelogenin interactions may be functionally involved in inhibiting amelogenin assembly, (ii) that such interactions facilitate amelogenin secretion, or (iii) that polypeptide motifs, comparable with the cytokeratin GMp1, occur within currently unidentified matrix proteins and have a functional role in normal enamel biomineralization.
